{"id":19592,"date":"2023-02-14T16:55:02","date_gmt":"2023-02-14T16:55:02","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/uk\/?page_id=19592"},"modified":"2026-03-26T14:54:54","modified_gmt":"2026-03-26T14:54:54","slug":"disclosures","status":"publish","type":"page","link":"https:\/\/www.neuraxpharm.com\/uk\/disclosures","title":{"rendered":"Disclosures \u2013 Working with Patient Organisations"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This page is intended for members of the public in the UK seeking information on Neuraxpharm UK business<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

NXUK\/2025\/01 | March 2026<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Neuraxpharm Disclosure<\/span><\/h1><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, our disclosure of payments to patient organisations and members of the public are published below.<\/p>

Neuraxpharm are committed to ensuring that these relationships and partnerships proceed within a principled framework of mutual respect, integrity and transparency for the benefit of patients, in line with the ABPI Code of Practice.\u00a0<\/p>

In the UK, the requirement to disclose Transfer of Value (ToV) on an individual basis is part of the ABPI Code of Practice. The information is published by the ABPI annually at the end of June. Further information about the disclosure of these payments can be found on the ABPI website: www.abpi.org.uk<\/a>\u00a0.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

2025 - Patient organisations<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\n\n\n\n\n\n\n\n\n
Name of organisation<\/b><\/th>\nDescription of support<\/b><\/th>\nAmount (\u00a3)<\/b><\/th>\n<\/tr>\n<\/thead>\n
Alex TLC<\/td>\nEducational Grant<\/td>\n\u00a320,000<\/td>\n<\/tr>\n
MS Academy<\/td>\nAnnual Sponsorship<\/td>\n\u00a355,000<\/td>\n<\/tr>\n
MS Together<\/td>\nEducational Grant<\/td>\n\u00a317,600<\/td>\n<\/tr>\n
MS Trust<\/td>\nCongress sponsorship<\/td>\n\u00a345,000<\/td>\n<\/tr>\n
Young Epilepsy<\/td>\nEducational Grant<\/td>\n\u00a39,000<\/td>\n<\/tr>\n\n<\/tbody>\n<\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

2025 - Members of the public<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
Number of members of the public contracted<\/th>Country<\/b><\/th>Contracted services provided<\/b><\/th>Description of support<\/b><\/th>Amount (\u00a3)<\/b><\/th><\/tr><\/thead>
1<\/td>UK<\/td>Fee<\/td>Workshop delivery \/ facilitation<\/td>\u00a312,564<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

2024<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
Name of organisation<\/b><\/th>Description of support<\/b><\/th>Amount (\u00a3)<\/b><\/th><\/tr><\/thead>
Alex TLC<\/td>Sponsorship of meeting<\/td>\u00a35,000<\/td><\/tr>
Yorkshire Paediatric Epilepsy Network (YPEN)<\/td>Sponsorship of meeting<\/td>\u00a3266<\/td><\/tr>
International League Against Epilepsy (ILAE)<\/td>Congress sponsorship<\/td>\u00a311,400<\/td><\/tr>
Epilepsy Nurses Association (ESNA)<\/td>Congress sponsorship<\/td>\u00a32,500<\/td><\/tr>
Eastern Epilepsy Nurses Association<\/td>Sponsorship of meeting<\/td>\u00a3180<\/td><\/tr>
NWEG \u2013 North West Epilepsy Group<\/td>Sponsorship of meeting<\/td>\u00a3360<\/td><\/tr>
Karger Publishing for Fast Facts Book: Epilepsy in Children and Young People (associated with ESNA)<\/td>Educational grant<\/td>\u00a315,000<\/td><\/tr>
British Paediatric Neurology Association (BPNA)<\/td>Sponsorship of Congress<\/td>\u00a33,000<\/td><\/tr>
West of England Seminars in Advanced Neurology (WESAN)<\/td>Sponsorship of meeting<\/td>\u00a31,954<\/td><\/tr>
Young Epilepsy<\/td>Sponsorship of meeting<\/td>\u00a312,375<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

2023<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Name of organisation<\/b><\/p><\/td>

Description of support<\/b><\/p><\/td>

Amount (\u00a3)<\/b><\/p><\/td><\/tr>

Alex TLC<\/p><\/td>

Sponsorship of meeting<\/p><\/td>

\u00a35,075<\/p><\/td><\/tr>

Young Epilepsy<\/p><\/td>

Educational grant\u00a0<\/p><\/td>

\u00a326,107<\/p><\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00a0<\/strong>
Our disclosure data is categorised as follows, with definitions provided by the ABPI Code of Practice 2024:<\/h3>


Donations and Grants<\/strong><\/p>

Neuraxpharm may provide donations or grants to support healthcare, scientific research, or educational initiatives. These contributions can take the form of funding, benefits\u2011in\u2011kind, or services that are freely given, with no expectation of goods or services in return.<\/p>

  • Donations<\/strong>\u00a0generally include physical items, services, or other non\u2011financial support.<\/li>
  • Grants<\/strong>\u00a0refer specifically to the provision of funds.<\/li><\/ul>

    Please note that donations and grants are\u00a0never provided to individuals<\/strong>, only to eligible organisations.<\/p>

    Sponsorship<\/strong><\/p>

    Neuraxpharm may also provide sponsorship for activities organised by independent entities such as healthcare organisations, patient organisations, or scientific bodies. Sponsorship may involve financial or non\u2011financial support for events, meetings, educational activities, or the development of materials.<\/p>

    A key distinction from grants is that sponsorship typically includes a\u00a0tangible benefit to the company<\/strong>, such as access to event participation or visibility associated with the activity.<\/p>

    \u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    NXUK\/MS\/0226\/49 | March 2026<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    This page is intended for members of the public in the UK seeking information on Neuraxpharm UK business NXUK\/2025\/01 | March 2026 Neuraxpharm Disclosure In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, our disclosure of payments to patient organisations and members of the public are published below. Neuraxpharm are […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-19592","page","type-page","status-publish","hentry"],"yoast_head":"\nDisclosures \u2013 Working with Patient Organisations - Neuraxpharm<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/uk\/disclosures\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Disclosures \u2013 Working with Patient Organisations\" \/>\n<meta property=\"og:description\" content=\"This page is intended for members of the public in the UK seeking information on Neuraxpharm UK business NXUK\/2025\/01 | March 2026 Neuraxpharm Disclosure In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, our disclosure of payments to patient organisations and members of the public are published below. Neuraxpharm are […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/uk\/disclosures\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-26T14:54:54+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.neuraxpharm.com\/uk\/disclosures\",\"url\":\"https:\/\/www.neuraxpharm.com\/uk\/disclosures\",\"name\":\"Disclosures \u2013 Working with Patient Organisations - Neuraxpharm\",\"isPartOf\":{\"@id\":\"https:\/\/www.neuraxpharm.com\/uk\/#website\"},\"datePublished\":\"2023-02-14T16:55:02+00:00\",\"dateModified\":\"2026-03-26T14:54:54+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.neuraxpharm.com\/uk\/disclosures\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.neuraxpharm.com\/uk\/#website\",\"url\":\"https:\/\/www.neuraxpharm.com\/uk\/\",\"name\":\"Neuraxpharm\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.neuraxpharm.com\/uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Disclosures \u2013 Working with Patient Organisations - Neuraxpharm","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/uk\/disclosures","og_locale":"en_US","og_type":"article","og_title":"Disclosures \u2013 Working with Patient Organisations","og_description":"This page is intended for members of the public in the UK seeking information on Neuraxpharm UK business NXUK\/2025\/01 | March 2026 Neuraxpharm Disclosure In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, our disclosure of payments to patient organisations and members of the public are published below. Neuraxpharm are […]","og_url":"https:\/\/www.neuraxpharm.com\/uk\/disclosures","og_site_name":"Neuraxpharm","article_modified_time":"2026-03-26T14:54:54+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/uk\/disclosures","url":"https:\/\/www.neuraxpharm.com\/uk\/disclosures","name":"Disclosures \u2013 Working with Patient Organisations - Neuraxpharm","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/uk\/#website"},"datePublished":"2023-02-14T16:55:02+00:00","dateModified":"2026-03-26T14:54:54+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/uk\/disclosures"]}]},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/uk\/#website","url":"https:\/\/www.neuraxpharm.com\/uk\/","name":"Neuraxpharm","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/uk\/wp-json\/wp\/v2\/pages\/19592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/uk\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/uk\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/uk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/uk\/wp-json\/wp\/v2\/comments?post=19592"}],"version-history":[{"count":74,"href":"https:\/\/www.neuraxpharm.com\/uk\/wp-json\/wp\/v2\/pages\/19592\/revisions"}],"predecessor-version":[{"id":20968,"href":"https:\/\/www.neuraxpharm.com\/uk\/wp-json\/wp\/v2\/pages\/19592\/revisions\/20968"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/uk\/wp-json\/wp\/v2\/media?parent=19592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}